Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2026 07:30 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell...
February 05, 2026 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
December 08, 2025 01:30 ET | Source: Cellectis Inc.

ASH 2025 : Cellectis présente son plan de développement pour renforcer les taux de réponse élevés obtenus avec éti-cel dans le LNH en rechute ou réfractaire

Éti-cel a montré un taux de réponse globale (ORR) de 88 % et un taux de réponse complète (CR) de 63 % (n=8) au niveau de dose actuel chez des patients atteints de LNH en rechute ou réfractaire après...
December 08, 2025 01:30 ET | Source: Cellectis Inc.

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion...
December 07, 2025 16:30 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete...
December 05, 2025 05:41 ET | Source: Research and Markets

CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035 by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players

Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035: Distribution by Target Antigens, Target Indication, Key Geographies, Sales...
December 01, 2025 09:46 ET | Source: Research and Markets

CAR-T Cell Therapy Forecast Report 2025: A $13.25 Billion Market by 2030, Driven by Rising Cancer Incidence, Strong Efficacy in R/R Patients, and Growing R&D Investment

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
November 27, 2025 08:43 ET | Source: Research and Markets

KLK2-Targeted Immunotherapies Pipeline Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of KLK2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 10, 2025 07:30 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic...
October 07, 2025 02:40 ET | Source: Cellectis Inc.

Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...